Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission.
Walter RB, Sandmaier BM, Othus M, Orvain C, Rodríguez-Arbolí E, Oshima MU, Schoch G, Davis C, Joachim Deeg H, Storb R. Walter RB, et al. Bone Marrow Transplant. 2023 Apr;58(4):377-385. doi: 10.1038/s41409-022-01909-x. Epub 2022 Dec 28. Bone Marrow Transplant. 2023. PMID: 36577856 Free PMC article.
Allocation to Matched Related or Unrelated Donor Results in Similar Clinical Outcomes without Increased Risk of Failure to Proceed to Transplant among Patients with Acute Myeloid Leukemia: A Retrospective Analysis from the Time of Transplant Approval.
Rodríguez-Arbolí E, Márquez-Malaver FJ, Rodríguez-Torres N, Caballero-Velázquez T, Escamilla-Gómez V, Calderón-Cabrera C, Falantes-González JF, Solé-Rodríguez M, García-Ramírez P, Moya-Arnao M, Carreras E, Espigado-Tocino I, Pérez-Simón JA. Rodríguez-Arbolí E, et al. Biol Blood Marrow Transplant. 2019 Jan;25(1):183-190. doi: 10.1016/j.bbmt.2018.08.019. Epub 2018 Aug 25. Biol Blood Marrow Transplant. 2019. PMID: 30153492 Free article.
Long-Term Impact of an Educational Antimicrobial Stewardship Program on Management of Patients with Hematological Diseases.
Guisado-Gil AB, Aguilar-Guisado M, Peñalva G, Lepe JA, Espigado I, Rodríguez-Arbolí E, González-Campos J, Rodríguez-Torres N, Montero-Cuadrado MI, Falantes-González JF, Reguera-Ortega JL, Gil-Navarro MV, Molina J, Pérez-Simón JA, Cisneros JM. Guisado-Gil AB, et al. Antibiotics (Basel). 2021 Jan 30;10(2):136. doi: 10.3390/antibiotics10020136. Antibiotics (Basel). 2021. PMID: 33573180 Free PMC article.
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study.
Rodríguez-Arbolí E, Martínez-Cuadrón D, Rodríguez-Veiga R, Carrillo-Cruz E, Gil-Cortés C, Serrano-López J, Bernal Del Castillo T, Martínez-Sánchez MDP, Rodríguez-Medina C, Vidriales B, Bergua JM, Benavente C, García-Boyero R, Herrera-Puente P, Algarra L, Sayas-Lloris MJ, Fernández R, Labrador J, Lavilla-Rubira E, Barrios-García M, Tormo M, Serrano-Maestro A, Sossa-Melo CL, García-Belmonte D, Vives S, Rodríguez-Gutiérrez JI, Albo-López C, Garrastazul-Sánchez MP, Colorado-Araujo M, Mariz J, Sanz MÁ, Pérez-Simón JA, Montesinos P; PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular) Cooperative Groups. Rodríguez-Arbolí E, et al. Transplant Cell Ther. 2021 Apr;27(4):311.e1-311.e10. doi: 10.1016/j.jtct.2020.12.029. Epub 2021 Jan 8. Transplant Cell Ther. 2021. PMID: 33836871 Free article.
Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.
Caballero-Velázquez T, Pérez-López O, Yeguas Bermejo A, Rodríguez Arbolí E, Colado Varela E, Sempere Talens A, Vidriales MB, Solé-Rodríguez M, Quirós Caso C, Pérez López E, Reinoso Segura M, Prats-Martín C, Montesinos P, Pérez-Simón JA. Caballero-Velázquez T, et al. Among authors: rodriguez arboli e. Cancers (Basel). 2023 Mar 5;15(5):1609. doi: 10.3390/cancers15051609. Cancers (Basel). 2023. PMID: 36900400 Free PMC article.
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.
Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Rodriguez-Arboli E, Bilbao C, Prados de la Torre E, Martínez-Cuadrón D, Rodríguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua J, Algarra L, Tormo M, Martínez-Sánchez P, Soria E, Serrano J, Alonso-Dominguez JM, García R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, Martínez-López J, Calasanz MJ, García-Sanz R, Pérez-Simón JA, Gómez Casares MT, Sánchez-García J, Barragán E, Montesinos P; PETHEMA cooperative study group. Sargas C, et al. Among authors: rodriguez arboli e. Blood Cancer J. 2023 May 12;13(1):77. doi: 10.1038/s41408-023-00835-5. Blood Cancer J. 2023. PMID: 37173322 Free PMC article.
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials.
Rodríguez-Arbolí E, Lee CJ, Caballero-Velázquez T, Martínez C, García-Calderón C, Jiménez-León MR, Bermúdez-Rodríguez MA, López-Corral L, Triguero A, Onstad L, Horwitz ME, Sarantopoulos S, Lee SJ, Pérez-Simón JA. Rodríguez-Arbolí E, et al. Clin Cancer Res. 2023 Oct 13;29(20):4057-4067. doi: 10.1158/1078-0432.CCR-23-0666. Clin Cancer Res. 2023. PMID: 37698881
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
Rodríguez-Arbolí E, Labopin M, Eder M, Brecht A, Blau IW, Huynh A, Forcade E, Tischer J, Bethge W, Bondarenko S, Verbeek M, Bulabois CE, Einsele H, Stölzel F, Savani B, Spyridonidis A, Bazarbachi A, Giebel S, Brissot E, Schmid C, Nagler A, Mohty M. Rodríguez-Arbolí E, et al. Bone Marrow Transplant. 2022 Jun;57(6):934-941. doi: 10.1038/s41409-022-01611-y. Epub 2022 Apr 7. Bone Marrow Transplant. 2022. PMID: 35393528
26 results